Technical Analysis for GLPG - Galapagos NV

Grade Last Price % Change Price Change
B 56.46 3.10% 1.70
GLPG closed up 3.1 percent on Thursday, January 20, 2022, on 3.25 times normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up
Historical GLPG trend table...

Date Alert Name Type % Chg
Pocket Pivot Bullish Swing Setup 0.00%
Volume Surge Other 0.00%
Gapped Up Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Crossed Above 20 DMA Bullish 3.10%
MACD Bullish Signal Line Cross Bullish 3.10%
180 Bullish Setup Bullish Swing Setup 3.10%
Inside Day Range Contraction 3.10%
Bearish Engulfing Bearish 4.87%
Fell Below 20 DMA Bearish 4.87%
Older End-of-Day Signals for GLPG ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout about 14 hours ago
Rose Above Upper Bollinger Band about 14 hours ago
Upper Bollinger Band Resistance about 15 hours ago
Possible Pocket Pivot about 17 hours ago
Up 3% about 17 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Galapagos NV Description

Galapagos NV, a clinical stage biotech company, develops and commercializes novel medicines in Belgium, Croatia, France, and the Netherlands. Its products include GLPG0634, an orally-available selective inhibitor of Janus kinase 1, which is in Phase II clinical study for the treatment of rheumatoid arthritis and other inflammatory diseases; and GLPG1205/GLPG1690 that is in Phase IIA clinical study for treating inflammatory bowel disease, as well as in Phase II proof-of-concept study for the treatment of ulcerative colitis patients. The company is also developing MOR106, an antibody, which is in preclinical development stage for the treatment of inflammatory diseases; GSK2586184, an investigational compound that is in Phase II clinical study for the treatment of chronic immuno-inflammatory diseases consisting of SLE, psoriasis, and ulcerative colitis; and GLPG0974, an orally available small molecule, which is in Phase II clinical study to prevent free fatty acid-induced activation and migration of neutrophils towards an inflammatory site, such as in the gut of patients with inflammatory bowel disease. It has strategic alliances with GlaxoSmithKline, MorphoSys, Servier, and AbbVie to discover and develop small molecules for the treatment of inflammation, inflammatory diseases, osteoarthritis, oncology, rheumatoid arthritis/crohn's disease, and cystic fibrosis diseases. The company was founded in 1999 and is headquartered in Mechelen, Belgium.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Immunology Acid Clinical Development Autoimmune Disease Inflammation Monoclonal Antibodies Inflammatory Diseases Rheumatoid Arthritis Psoriasis Inflammatory Bowel Disease Ulcer Osteoarthritis Ulcerative Colitis Colitis Cystic Fibrosis Abdominal Pain Fatty Acids Arthritis Janus Kinase Treatment Of Inflammatory Disease Treatment Of Inflammatory Diseases Mechel Morphosys Treatment Of Inflammation

Is GLPG a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 112.01
52 Week Low 46.41
Average Volume 268,088
200-Day Moving Average 61.60
50-Day Moving Average 52.26
20-Day Moving Average 53.99
10-Day Moving Average 53.18
Average True Range 1.77
ADX 17.32
+DI 36.44
-DI 18.45
Chandelier Exit (Long, 3 ATRs) 52.12
Chandelier Exit (Short, 3 ATRs) 55.67
Upper Bollinger Bands 57.27
Lower Bollinger Band 50.71
Percent B (%b) 0.88
BandWidth 12.14
MACD Line 0.52
MACD Signal Line 0.32
MACD Histogram 0.2001
Fundamentals Value
Market Cap 3.69 Billion
Num Shares 65.3 Million
EPS -1.69
Price-to-Earnings (P/E) Ratio -33.49
Price-to-Sales 14.69
Price-to-Book 2.45
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 58.77
Resistance 3 (R3) 58.84 58.14 58.38
Resistance 2 (R2) 58.14 57.55 58.10 58.25
Resistance 1 (R1) 57.30 57.19 57.72 57.23 58.13
Pivot Point 56.60 56.60 56.81 56.56 56.60
Support 1 (S1) 55.76 56.01 56.18 55.69 54.79
Support 2 (S2) 55.06 55.65 55.03 54.67
Support 3 (S3) 54.22 55.06 54.54
Support 4 (S4) 54.15